May 13th 2022
Mark T. Fleming, MD, discusses the rationale and results from the phase 3 SPOTLIGHT trial in prostate cancer.
April 8th 2022
Prostate cancer is the most common cancer in men and the second-leading cause of cancer-related deaths in men in the US.
March 2nd 2019
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life in recent prostate cancer clinical trials.